Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Tolerance inks $260M deal for thymus-targeting fusion protein
Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein.
Nick Paul Taylor
Aug 19, 2026 10:00am
CytoDyn’s leronlimab reaffirms HIV potential with macaque study
Aug 12, 2026 4:30am
GSK unveils cost-saving plan to fund R&D, move research HQ
Jul 28, 2026 9:50am
Fierce Pharma
Merck prepares expanded access to monthly PrEP pill early
Jul 24, 2026 10:40am
Gilead cancels HIV trial as clinical hold remains intact
Apr 1, 2026 4:50pm
After R&D head exits, Immunocore CEO pairs ambition with caution
Feb 13, 2026 12:44pm
